We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Resmed Inc | ASX:RMD | Australian Stock Exchange | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.04 | -0.12% | 32.96 | 32.90 | 33.00 | 33.27 | 32.84 | 33.08 | 2,135,770 | 07:20:01 |
Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
ResMed Inc. (NYSE: RMD, ASX: RMD), a world-leading connected health company, today announced results for its quarter ended June 30, 2019.
Fourth Quarter 2019 Highlights
Full Year 2019 Highlights
“We finished fiscal year 2019 with double-digit revenue growth to $2.6 billion and operating profit up 18% on a non-GAAP basis. Recent mask launches have driven market share gains while continued adoption of our SaaS solutions is driving both revenue growth and a steady margin profile,” said Mick Farrell, ResMed’s CEO. “We delivered another quarter of operating leverage, which gives us flexibility as we execute on our long-term strategy to provide innovative products, software, and solutions to improve health outcomes, create efficiencies, and reduce overall healthcare system costs. Our pipeline is solid; we are well-positioned as we enter fiscal year 2020 on a trajectory to improve 250 million lives in out-of-hospital healthcare in 2025.”
Financial Results and Operating Metrics Unaudited; $ in millions, except for per share amounts
Three Months Ended
June 30, 2019
June 30, 2018
% Change
Constant Currency (A)
Revenue
$
705.0
$
623.6
13
%
15
%
Gross margin
59.3
%
58.1
%
2
Selling, general and administrative expenses
171.6
156.8
9
14
Research and development expenses
51.1
39.7
29
32
Income from operations
121.1
146.9
(18)
Non-GAAP income from operations (B)
196.2
166.0
18
Net income
68.8
109.8
(37)
Non-GAAP net income (B)
137.6
136.3
1
Diluted earnings per share
$
0.48
$
0.76
(37)
Non-GAAP diluted earnings per share (B)
$
0.95
$
0.95
-
Twelve Months Ended
June 30, 2019
June 30, 2018
% Change
Constant Currency (A)
Revenue
$
2,606.6
$
2,340.2
11
%
13
%
Gross margin
59.0
%
58.2
%
1
Selling, general and administrative expenses
645.0
600.4
7
11
Research and development expenses
180.7
155.1
16
20
Income from operations
579.3
541.8
7
Non-GAAP income from operations (B)
716.3
606.6
18
Net income
404.6
315.6
28
Non-GAAP net income (B)
526.4
507.8
4
Diluted earnings per share
$
2.80
$
2.19
28
Non-GAAP diluted earnings per share (B)
$
3.64
$
3.53
3
(A)
In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency basis”, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.
(B)
See the reconciliation of non-GAAP financial measures in the table at the end of the press release.
Discussion of Fourth Quarter Results
Other Business and Operational Highlights
Dividend program
The ResMed board of directors today declared a quarterly cash dividend of $0.39 per share, an increase of 5% compared to the most recent quarterly dividend of $0.37 per share. The dividend will have a record date of August 15, 2019, payable on September 19, 2019. The dividend will be paid in U.S. currency to holders of ResMed’s common stock trading on the New York Stock Exchange. Holders of Chess Depositary Instruments trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be August 14, 2019 for common stockholders and for CDI holders. ResMed has received a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from August 14, 2019 through August 15, 2019, inclusive.
Webcast details
ResMed will discuss its fourth quarter fiscal year 2019 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on ResMed’s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q4 2019 Earnings Webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on our website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately two hours after the webcast by dialing +1 800-585-8367 (U.S.) or +1 416-621-4642 (outside U.S.) and entering the passcode 2699213. The telephone replay will be available until August 8, 2019.
About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our cloud-connected medical devices transform care for people with sleep apnea, COPD and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries. To learn more, visit ResMed.com and follow @ResMed.
Safe harbor statement
Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding ResMed’s projections of future revenue or earnings, expenses, new product development, new product launches, new markets for its products, the integration of acquisitions, litigation, and tax outlook – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed’s periodic reports on file with the U.S. Securities & Exchange Commission. ResMed does not undertake to update its forward-looking statements.
RESMED INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Income (Unaudited; $ in thousands, except for per share amounts)
Three Months Ended
Twelve Months Ended
June 30, 2019
June 30, 2018
June 30, 2019
June 30, 2018
Net revenue
$
704,964
$
623,631
$
2,606,572
$
2,340,196
Cost of sales
287,114
261,159
1,069,987
978,032
Gross profit
$
417,850
$
362,472
$
1,536,585
$
1,362,164
Operating expenses:
Selling, general and administrative
171,600
156,810
645,010
600,369
Research and development
51,138
39,657
180,651
155,149
Amortization of acquired intangible assets (1)
23,437
11,611
74,938
46,383
Restructuring expenses (1)
9,401
7,510
9,401
18,432
Litigation settlement expenses (1)
41,199
-
41,199
-
Acquisition related expenses (1)
-
-
6,123
-
Total operating expenses
$
296,775
$
215,588
$
957,322
$
820,333
Income from operations (1)
121,075
146,884
579,263
541,831
Other income (expenses), net:
Interest income (expense), net
$
(12,264)
$
(2,780)
$
(33,857)
$
(11,977)
Loss attributable to equity method investments
(6,463)
-
(15,833)
-
Other, net
(6,587)
(3,185)
(10,726)
(8,542)
Total other income (expenses), net
(25,314)
(5,965)
(60,416)
(20,519)
Income before income taxes
$
95,761
$
140,919
$
518,847
$
521,312
Income taxes
26,964
31,107
114,255
205,724
Net income
$
68,797
$
109,812
$
404,592
$
315,588
Basic earnings per share
$
0.48
$
0.77
$
2.83
$
2.21
Diluted earnings per share
$
0.48
$
0.76
$
2.80
$
2.19
Non-GAAP diluted earnings per share (1)
$
0.95
$
0.95
$
3.64
$
3.53
Basic shares outstanding
143,435
142,793
143,111
142,764
Diluted shares outstanding
144,687
144,004
144,484
143,987
(1)
See the reconciliation of non-GAAP financial measures in the table at the end of the press release.
RESMED INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets (Unaudited; $ in thousands)
June 30, 2019
June 30, 2018
ASSETS
Current assets:
Cash and cash equivalents
$
147,128
$
188,701
Accounts receivable, net
528,484
483,681
Inventories
349,641
268,701
Prepayments and other current assets
120,113
124,634
Total current assets
$
1,145,366
$
1,065,717
Non-current assets:
Property, plant and equipment, net
$
387,460
$
386,550
Goodwill and other intangibles, net
2,378,399
1,284,128
Deferred income taxes and other non-current assets
196,457
327,528
Total non-current assets
$
2,962,316
$
1,998,206
Total assets
$
4,107,682
$
3,063,923
LIABILITIES AND STOCKHOLDERS’ EQUITY:
Current liabilities:
Accounts payable
$
115,725
$
92,723
Accrued expenses
266,359
185,805
Deferred revenue
88,667
60,828
Income taxes payable
73,248
160,427
Short-term debt
11,992
11,466
Total current liabilities
$
555,991
$
511,249
Non-current liabilities:
Deferred revenue
$
81,143
$
71,596
Deferred income taxes
11,380
13,084
Other long term liabilities
2,058
924
Long-term debt
1,258,861
269,988
Long-term income taxes payable
126,056
138,102
Total non-current liabilities
$
1,479,498
$
493,694
Total liabilities
$
2,035,489
$
1,004,943
STOCKHOLDERS’ EQUITY:
Common stock
$
575
$
571
Additional paid-in capital
1,511,473
1,450,821
Retained earnings
2,436,410
2,432,328
Treasury stock
(1,623,256)
(1,600,412)
Accumulated other comprehensive income
(253,009)
(224,328)
Total stockholders’ equity
$
2,072,193
$
2,058,980
Total liabilities and stockholders' equity
$
4,107,682
$
3,063,923
RESMED INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows (Unaudited; $ in thousands)
Twelve Months Ended
June 30, 2019
June 30, 2018
Cash flows from operating activities:
Net income
$
404,592
$
315,588
Adjustment to reconcile net income to cash provided by operating activities:
Depreciation and amortization
150,795
119,960
Stock-based compensation costs
52,073
48,412
Loss attributable to equity method investments
15,833
-
Impairment of equity investments
15,007
11,593
Gain on previously held equity interest
(1,909)
-
Changes in fair value of business combination contingent consideration
(286)
411
Changes in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net
(18,013)
(32,356)
Inventories, net
(84,188)
1,494
Prepaid expenses, net deferred income taxes and other current assets
(47,575)
(160,726)
Accounts payable, accrued expenses and other
(27,278)
200,650
Net cash provided by operating activities
$
459,051
$
505,026
Cash flows from investing activities:
Purchases of property, plant and equipment
(68,710)
(62,581)
Patent registration costs
(8,632)
(8,876)
Business acquisitions, net of cash acquired
(951,383)
(902)
Purchases of investments
(46,717)
(14,495)
Proceeds / (Payments) on maturity of foreign currency contracts
(264)
(14,970)
Net cash used in investing activities
$
(1,075,706)
$
(101,824)
Cash flows from financing activities:
Proceeds from issuance of common stock, net
36,727
38,717
Taxes paid related to net share settlement of equity awards
(28,104)
(15,385)
Purchases of treasury stock
(22,844)
(53,801)
Payment of business combination contingent consideration
(909)
(486)
Proceeds from borrowings, net of borrowing costs
1,519,230
350,000
Repayment of borrowings
(711,745)
(1,146,242)
Dividends paid
(211,712)
(199,497)
Net cash (used in) / provided by financing activities
$
580,643
$
(1,026,694)
Effect of exchange rate changes on cash
$
(5,561)
$
(9,742)
Net increase / (decrease) in cash and cash equivalents
(41,573)
(633,234)
Cash and cash equivalents at beginning of period
188,701
821,935
Cash and cash equivalents at end of period
$
147,128
$
188,701
RESMED INC. AND SUBSIDIARIES
Reconciliation of Non-GAAP Financial Measures (Unaudited; $ in thousands, except for per share amounts)
The measure, “non-GAAP income from operations” is reconciled with GAAP income from operations below:
Three Months Ended
Twelve Months Ended
June 30, 2019
June 30, 2018
June 30, 2019
June 30, 2018
GAAP income from operations
$
121,075
$
146,884
$
579,263
$
541,831
Amortization of acquired intangible assets (A)
23,437
11,611
74,938
46,383
Deferred revenue fair value adjustment (A)
1,065
-
5,348
-
Restructuring expenses (A)
9,401
7,510
9,401
18,432
Litigation settlement expenses (A)
41,199
-
41,199
-
Acquisition related expenses (A)
-
-
6,123
-
Non-GAAP income from operations
$
196,177
$
166,005
$
716,272
$
606,646
The measures "non-GAAP net income" and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:
Three Months Ended
Twelve Months Ended
June 30, 2019
June 30, 2018
June 30, 2019
June 30, 2018
GAAP net income
$
68,797
$
109,812
$
404,592
$
315,588
Amortization of acquired intangible assets, net of tax (A)
17,401
8,435
57,246
33,694
Deferred revenue fair value adjustment, net of tax (A)
786
-
4,067
-
Acquisition-related expenses (A)
-
-
5,362
-
Restructuring expenses, net of tax (A)
7,205
5,013
7,205
13,328
Litigation settlement expenses, net of tax (A)
36,248
-
36,248
-
Fair value impairment of investment (A)
5,000
-
5,000
-
U.S. tax reform
2,149
5,792
6,654
138,016
Foreign tax credit adjustment (A)
-
7,204
-
7,204
Non-GAAP net income (A)
$
137,586
$
136,256
$
526,374
$
507,830
Diluted shares outstanding
144,687
144,004
144,484
143,987
GAAP diluted earnings per share
$
0.48
$
0.76
$
2.80
$
2.19
Non-GAAP diluted earnings per share (A)
$
0.95
$
0.95
$
3.64
$
3.53
(A)
ResMed adjusts for the impact of the amortization of acquired intangibles, deferred revenue fair value adjustment, acquisition-related expenses, restructuring-related expenses, litigation settlement expenses, fair value impairment of investment, and the impact of U.S. tax reform on income tax expense, from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.
ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight when evaluating ResMed’s performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.
RESMED INC. AND SUBSIDIARIES
Revenue by Product and Region (Unaudited; $ in thousands, except for per share amounts)
Three Months Ended
June 30, 2019
June 30, 2018
% Change
Constant Currency (A)
U.S., Canada and Latin America
Devices
$
202.9
$
189.9
7
%
Masks and other
182.6
156.8
16
Total Sleep and Respiratory Care
$
385.5
$
346.7
11
Software as a Service
85.2
40.4
111
Total
$
470.7
$
387.1
22
Combined Europe, Asia and other markets
Devices
$
155.5
$
162.2
- 4
%
1
%
Masks and other
78.8
74.3
6
12
Total Sleep and Respiratory Care
$
234.3
$
236.5
- 1
4
Global revenue
Devices
$
358.4
$
352.1
2
%
4
%
Masks and other
261.4
231.1
13
15
Total Sleep and Respiratory Care
$
619.8
$
583.2
6
8
Software as a Service
85.2
40.4
111
111
Total
$
705.0
$
623.6
13
15
Twelve Months Ended
June 30, 2019
June 30, 2018
% Change
Constant Currency (A)
U.S., Canada and Latin America
Devices
$
743.1
$
689.6
8
%
Masks and other
677.4
600.5
13
Total Sleep and Respiratory Care
$
1,420.5
$
1,290.1
10
Software as a Service
275.8
157.0
76
Total
$
1,696.3
$
1,447.1
17
Combined Europe, Asia and other markets
Devices
$
618.5
$
614.0
1
%
5
%
Masks and other
291.8
279.1
5
9
Total Sleep and Respiratory Care
$
910.3
$
893.1
2
6
Global revenue
Devices
$
1,361.6
$
1,303.6
4
%
6
%
Masks and other
969.2
879.6
10
12
Total Sleep and Respiratory Care
$
2,330.8
$
2,183.2
7
9
Software as a Service
275.8
157.0
76
76
Total
$
2,606.6
$
2,340.2
11
13
(A)
In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency basis”, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190725005777/en/
For investors Amy Wakeham +1 858-836-5000 investorrelations@resmed.com
For media Jayme Rubenstein +1 858-836-6798 news@resmed.com
1 Year Resmed Chart |
1 Month Resmed Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions